Sartorius AG Preference Shares

Sartorius AG Preference Shares represent a class of non-voting equity in Sartorius AG, a leading supplier of laboratory and bioprocess solutions for the life sciences and biopharmaceutical industries. These shares primarily grant holders preferential dividend rights, often at higher rates than ordinary shares, appealing to investors prioritizing income stability over corporate governance influence. Sartorius AG, headquartered in Göttingen, Germany, and founded in 1870, develops innovative instruments like pipettes, balances, and water purification systems, alongside bioprocess technologies for drug discovery, development, and manufacturing of biologics, vaccines, and therapies. The company operates through Bioprocess Solutions and Lab Products & Services divisions, serving pharmaceutical, biotechnology, research institutes, and industries such as oncology, immunology, and cell therapy globally with around 13,685 employees. With 34,813,621 preference shares outstanding (excluding treasury shares), these instruments underscore Sartorius AG's pivotal role in advancing biopharmaceutical innovation and supporting scalable production processes amid growing demand for advanced therapies.